ALL NEWS

FDA advisers unanimously recommend booster doses of Johnson & Johnson’s Covid-19 vaccine

Oct 15, 2021, 11:32 AM | Updated: 12:12 pm
FILE - In this April 13, 2021, file photo, a box of Johnson & Johnson vaccines are shown by pha...
FILE - In this April 13, 2021, file photo, a box of Johnson & Johnson vaccines are shown by pharmacist Zsolt Szenasi at a warehouse of Hungaropharma, a Hungarian pharmaceutical wholesale company, in Budapest, Hungary. Johnson & Johnson released data showing that a booster dose to its one-shot coronavirus vaccine provides a strong immune response months after people receive a first dose.i n a statement on Tuesday, Sept. 21, 2021, J&J said it ran two early studies in people previously given its vaccine and found that a second dose produced an increased antibody response in adults aged 18 to 55. The study results have not yet been peer-reviewed. (Szilard Koszticsak/MTI via AP, File)
(Szilard Koszticsak/MTI via AP, File)

    (CNN) — Vaccine advisers to the US Food and Drug Administration voted unanimously Friday to recommend a booster dose of Johnson & Johnson’s vaccine at least two months after people get the first dose.

The FDA’s Vaccines and Related Biological Products Advisory Committee voted 19-0 to recommend the extra dose for all recipients of the J&J Janssen vaccine, 18 and older. They asked to simplify the original question being posed by the FDA, which had asked the committee to say whether the data showed that waiting six months or longer after getting the first shot would provide an even stronger immune response.

The FDA will now consider the committee’s advice. Then the US Centers for Disease Control and Prevention’s vaccine advisers will be asked to consider it.

Johnson & Johnson says studies have shown boosting at two or six months can bring that effectiveness up to 94% and it says its effectiveness does not wane over time in the same way that effectiveness from Pfizer’s vaccine does.

But the Johnson & Johnson vaccine has not been shown to be as protective as either the Pfizer or Moderna vaccines, noted VRBPAC chair Dr. Arnold Monto, a professor of public health and epidemiology at the University of Michigan. “So there is some urgency here to do something,” he told the meeting.

And the CDC’s Dr. Amanda Cohn told the meeting that various studies suggested real-world efficacy of J&J’s vaccine was anywhere between 50% and 68%.

“Regardless of whether or not there been waning or this is the true effectiveness after a single dose, the effectiveness or protection of a single dose of the J&J vaccine is not equivalent to protection at this time with either two doses of an mRNA vaccine and certainly not in those groups who have now been authorized to receive a booster dose of an mRNA vaccine,” Cohn said.

Members of the committee said while there was not much data to show whether the efficacy of the Janssen vaccine was waning — or was strong to begin with — they agreed people should be given the opportunity for a booster. “I would say I agree a second dose booster is needed to boost immunity back to the 90-plus range,” Dr. Archana Chatterjee, a pediatric infectious diseases expert at Rosalind Franklin University in Chicago, said before the vote.

The FDA has already given EUA to a booster for Pfizer’s vaccine for people who are six months out from their first two shots who are also either 65 or older or who are at least 18 and have a higher risk of severe disease because of pre-existing conditions or because of work or living conditions.

And Americans are already flocking to get those boosters. Data from the US Centers for Disease Control and Prevention show close to 5% of fully vaccinated people — about 9 million people — have received booster shots.

On Thursday, VRBPAC members voted unanimously to recommend booster doses of Moderna’s vaccine to the same groups.

If the FDA gives emergency use authorization to Moderna or Johnson & Johnson boosters, CDC vaccine advisers will meet to discuss which groups to recommend them to. Typically, shots can be administered once the CDC director signs off on the recommendation. CDC’s Advisory Committee on Immunization Practices is scheduled to discuss boosters on October 21.

The-CNN-Wire
™ & © 2021 Cable News Network, Inc., a WarnerMedia Company. All rights reserved.

Today’s Top Stories

All News

Crumbley mug shots...
By Carolyn Sung, Shimon Prokupecz and Jason Hanna, CNN

Parents of Michigan school shooting suspect held on $500,000 bond each after manhunt

Parents of Michigan school shooter captured and held on bond.
20 hours ago
missionary injured in shooting seventy missionaries are safe...
Karilyn Frazier

Church missionary serving in Alabama injured in a shooting

The Church of Jesus Christ of Latter Day Saint missionary is injured in a shooting.
20 hours ago
winds may be to blame paraglider9-year-old boy taser swat dog dynamite evacuation shoplifter injury...
Karilyn Frazier

Winds may be to blame in paraglider accident near Traverse Mountain

Winds may be to blame for a accident involving a paraglider.
20 hours ago
chief scientist Utah lab Salt Lake company corona virus...
Kelsey Earl

Chief scientist at Utah Lab helps identify Omicron in Utah

The Chief Scientist at a Utah lab helped spot the Omicron variant in Utah.
20 hours ago
U of U Utes win...
Mark Jackson

U of U Utes win first Pac-12 championship; heading to the Rose Bowl

U of U Utes win their first Pacific 12 Conference Championship.
20 hours ago
Omicron variant Photo: Canva...
Becky Bruce

Omicron variant of COVID-19 detected in first Utah patient

Utah health officials confirmed the state's first patient to test positive for the omicron variant of COVID-19 Friday. 
2 days ago
FDA advisers unanimously recommend booster doses of Johnson & Johnson’s Covid-19 vaccine